Mirtazapine
- Generic Name
- Mirtazapine
- Brand Names
- Remeron
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3
- CAS Number
- 85650-52-8
- Unique Ingredient Identifier
- A051Q2099Q
- Background
Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early as 1 week after beginning therapy.
In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.
- Indication
This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
Mirtazapine has been used off-label for a variety of conditions including panic disorder, generalized anxiety disorder, dysthymia, tension headaches, hot flushes, post-traumatic stress disorder (PTSD), sleep disorders, substance abuse disorders, and sexual disorders, among others.
- Associated Conditions
- Cancer Pain, Depression, Fibromyalgia, Generalized Anxiety Disorder, Hot Flashes, Insomnia, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Persistent Depressive Disorder (Dysthymia), Post Operative Nausea and Vomiting (PONV), Poststroke depression, Sleep disorders and disturbances, Substance Abuse Disorders, Tension Headache
Combined Mirtazapine and SSRI Treatment of PTSD: A Placebo-Controlled Trial
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- Research Foundation for Mental Hygiene, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01178671
- Locations
- 🇺🇸
Anxiety Disorders Clinic, New York State Psychiatric Institute, New York, New York, United States
A Study of Quetiapine and Mirtazapine for the Treatment of Alcohol Dependency
- Conditions
- Alcohol Dependence
- Interventions
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01165541
- Locations
- 🇺🇸
Dartmouth Medical School Department of Psychiatry's Addition Research Center, Bedford, New Hampshire, United States
🇺🇸Dartmouth Medical School Department of Psychiatry's Addiction Research Center, Hanover, New Hampshire, United States
Strategic Use of New Generation Antidepressants for Depression
- Conditions
- Unipolar Major Depressive Episode
- Interventions
- First Posted Date
- 2010-04-23
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Kyoto University
- Target Recruit Count
- 2011
- Registration Number
- NCT01109693
- Locations
- 🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵Kochi Medical School Hospital, Nangoku, Kochi, Japan
Pharmacogenetic Study of Mirtazapine Response in Depressed Patients
- First Posted Date
- 2009-12-25
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT01039740
- Locations
- 🇰🇷
Samsung Medical Center, Kangnam, Seoul, Korea, Republic of
Mirtazapine Reduces ICD Shocks in ICD Patients With Depression and Anxiety
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2009-08-18
- Lead Sponsor
- Universidad Nacional de Rosario
- Target Recruit Count
- 40
- Registration Number
- NCT00960830
- Locations
- 🇦🇷
Cl Sn Nicol, San Nicolas, Bs As, Argentina
Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome
- First Posted Date
- 2009-06-12
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Mahidol University
- Target Recruit Count
- 80
- Registration Number
- NCT00919295
- Locations
- 🇹🇭
Siriraj Hospital, Mahidol University, Bangkoknoi, Bangkok, Thailand
Short-term Metabolic Effects of Mirtazapine in Healthy Subjects
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Max-Planck-Institute of Psychiatry
- Target Recruit Count
- 12
- Registration Number
- NCT00878540
- Locations
- 🇩🇪
Max Planck Institue of Psychiatry, Munich, Germany
The Effects of Mirtazapine Versus Placebo on Alcohol Consumption in Male Alcohol High Consumers
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2009-04-02
- Lead Sponsor
- Sahlgrenska University Hospital, Sweden
- Target Recruit Count
- 59
- Registration Number
- NCT00874003
- Locations
- 🇸🇪
Addiction Biology Unit, Gothenburg, Sweden
A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2010-08-17
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00865696
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
A Relative Bioavailability Study of Mirtazapine 15 mg Tablets Under Non-fasting Conditions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2009-03-19
- Last Posted Date
- 2010-08-17
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00865384
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.